Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis

[1]  S. Egawa,et al.  Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer , 2021, The Prostate.

[2]  G. Haas,et al.  LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) , 2021, Annals of Oncology.

[3]  K. Bevans,et al.  Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. D'Amico,et al.  NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Henk G van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.

[6]  R. V. D. van den Bergh,et al.  Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment. , 2020, European urology focus.

[7]  T. Habuchi,et al.  Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration‐sensitive prostate cancer: A multicenter retrospective study , 2020, International journal of urology : official journal of the Japanese Urological Association.

[8]  John L Pfail,et al.  Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial , 2020, Prostate Cancer and Prostatic Diseases.

[9]  A. Briganti,et al.  Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. , 2019, Clinical genitourinary cancer.

[10]  S. Shariat,et al.  Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis , 2019, International Journal of Clinical Oncology.

[11]  M. Sydes,et al.  Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Stockler,et al.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[13]  D. Ye,et al.  Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.

[14]  H. Miyake,et al.  Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer , 2019, AntiCancer Research.

[15]  D. Lam,et al.  A Territory‐wide, Multicenter, Age‐ and Prostate‐specific Antigen‐matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone‐sensitive Prostate Cancer , 2019, Clinical genitourinary cancer.

[16]  M. Gleave,et al.  The impact of time to metastasis on overall survival in patients with prostate cancer , 2018, World Journal of Urology.

[17]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Kantoff,et al.  Clinical Outcomes of First‐line Abiraterone Acetate or Enzalutamide for Metastatic Castration‐resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone‐sensitive Prostate Cancer , 2017, Clinical genitourinary cancer.

[19]  S. Egawa,et al.  Lactate dehydrogenase predicts combined progression‐free survival after sequential therapy with abiraterone and enzalutamide for patients with castration‐resistant prostate cancer , 2017, The Prostate.

[20]  S. Culine,et al.  Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. , 2016, European urology.

[21]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[22]  A. Oronsky,et al.  Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance , 2015, Neoplasia.

[23]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[24]  Takahito Hara,et al.  Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.

[25]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[26]  H. Akaza,et al.  Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. , 2008, Japanese journal of clinical oncology.

[27]  Peter C Austin,et al.  The performance of different propensity score methods for estimating marginal hazard ratios , 2007, Statistics in medicine.

[28]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[29]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[30]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[31]  H. Rao.  Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients , 1995, The Lancet.

[32]  Seung Woo Lee,et al.  Comparisons of therapeutic outcomes in patients with nonampullary duodenal neuroendocrine tumors (NADNETs) , 2019, Medicine.

[33]  Practicum Summary.  University of Texas Southwestern Medical Center Dallas, TX , 2013 .

[34]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[35]  M. Soloway,et al.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.